Corindus Vascular Robotics (CVRS) Reports In-Line Q2 EPS

Corindus Vascular Robotics (NYSE: CVRS) reported Q2 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $508 thousand versus the consensus estimate of $1.3 million.

"We achieved several strategic accomplishments in the second quarter, positioning Corindus for long term success as a key partner to hospitals and as a leader in cardiovascular robotics,” said Mark Toland, President and Chief Executive Officer of Corindus. “We have made meaningful progress in evaluating our operational goals and objectives, refining our strategic priorities, which lays the foundation for our success. Along with our new strategic direction, we have made changes at every level of the organization with a focus on accountability and operational excellence.”

Mr. Toland continued, “As we shift to a culture of empowerment across all functions, our goal is to effectively scale our business and advance our market position through targeted investment and strong execution. Looking ahead, our vision is to drive widespread adoption of cardiovascular robotics programs to streamline workflow for hospitals and improve the lives of patients and physicians globally.”

For earnings history and earnings-related data on Corindus Vascular Robotics (CVRS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c